New experimental treatment manages to reduce pulmonary fibrosis after a transplant

A new system with rapamycin nanoparticles reduces fibrosis and chronic rejection in an experimental model of lung transplantation.

Add DEMÓCRATA to Google

Ask FREN

Published

4 minutes

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 19 de noviembre de 2026 · 18 institutos

  • PP31,1 %
  • PSOE27,4 %
  • Vox19,1 %
  • Frente Amplio6,2 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

An international investigation, co-led by a team from the Instituto de Salud Carlos III (ISCIII), has designed an experimental therapeutic approach capable of reducing pulmonary fibrosis after a lung transplant and that could help prevent chronic rejection of the transplanted organ.

The lung is one of the organs with the worst long-term survival compared with other transplants. The main cause is chronic dysfunction of the lung graft, a form of chronic rejection in which the transplanted organ progressively scars, a process known as fibrosis, until it loses its function.

The immunosuppressive drugs that are currently administered to transplant patients mainly target cells of the adaptive immune system, in particular T and B lymphocytes. However, growing scientific evidence indicates that cells of the innate immune system, such as macrophages, monocytes, and neutrophils, play a key role in the onset of pulmonary chronic rejection.

The lung’s special susceptibility to chronic rejection is linked to its high load of innate immune cells and to its continuous exposure to air, to microorganisms, and to particles present in the environment.

These innate cells can acquire an inflammatory memory, called trained immunity. After an intense stimulus, such as the injury the organ suffers during transplantation, myeloid cells are reprogrammed and can drive chronic rejection over prolonged periods.

The mTOR protein is fundamental in that reprogramming, and for this reason mTOR inhibitors, including rapamycin, are already used in transplants. However, to date they have not demonstrated that they can prevent chronic rejection of lung transplant, in part because their toxicity limits reaching the doses needed to block trained immunity in myeloid cells.

Nanoparticles to deliver rapamycin to the lung

Scientists from the Centro Nacional de Microbiología of the ISCIII, from the Hospital Monte Sinai in New York, and from the University of Washington in St. Louis have overcome this barrier with a nanoparticle, called mTORi-NB, which transports rapamycin directly to lung tissue so that it can be taken up by the cells responsible for rejection.

mTORi-NB nano-structures are tiny lipid particles, of a size similar to that of a virus, formed from apolipoprotein A-I, the main component of HDL cholesterol, known as good cholesterol.

The work, published in 'American Journal of Transplantation', evaluated the effectiveness of this strategy in an experimental model of lung transplantation in a mouse that reproduces the fibrotic lesions typical of human chronic rejection. The animals received three intravenous doses of nanoparticles: on the same day as the transplant and on days two and five after the intervention.

The data obtained showed a protective effect in all the phases studied. During the first week, the treated lungs showed less cellular infiltration than the untreated ones and preserved an alveolar architecture that was almost normal, while the transplanted organs without therapy presented intense inflammation.

After two weeks, the treated lungs maintained type II alveolar cells, considered stem cells responsible for regenerating lung tissue, and these continued to divide. In the untreated organs, their proliferative capacity practically disappeared, and the degree of acute rejection was also lower in the mice that received the mTORi-NB nanoparticles.

By one month after transplantation, the treated lungs showed a marked reduction in fibrosis around bronchi and vessels, as well as less thickening of the pleura. In addition, the treatment favored the preservation of club cells in the bronchioles, the loss of which is associated with chronic rejection in patients.

Mechanism of action and next steps

Transcriptomic analysis of more than 21,000 cells from lung transplantation made it possible to clarify how mTORi-NB nanoparticles prevent the appearance of fibrosis.

In the treated lungs, macrophages decreased the expression of inflammatory and pro-fibrotic genes and increased that of genes with anti-fibrotic function. The effect also extended to cells that barely took up the nanoparticle, such as alveolar cells, which showed less activation of the TGF-beta pathway, one of the main drivers of fibrosis.

These findings indicate that, by reprogramming macrophages, the treatment modifies communication between myeloid cells and the rest of the lung cells. "These results show that acting on the inflammatory memory of innate immunity cells at the time of transplantation has lasting consequences," the coauthor of the study, Leticia Pérez-Rodríguez, has explained.

Pérez-Rodríguez, Sara Borrell researcher at the National Center of Microbiology of ISCIII, has emphasized the shift in the therapeutic paradigm that this proposal entails compared with systemic immunosuppression and immunosuppression maintained over time.

The same ISCIII team, led by Dr. Jordi Ochando, had already shown with a prior version of these nanoparticles that the use of mTORi-NB prevented acute rejection in an experimental model of heart transplantation.

In any case, the results come from an animal model and will need to be validated before being translated to patients. Dr. Ochando has advanced that the next phases of the research will include analyzing whether a longer treatment or one administered in later phases is capable of halting an already established fibrosis.